Gilead Sciences Aktie News

BofA Securities is the investment banking and capital markets division of Bank of America, one of the largest financial institutions in the United States.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...

Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats.

Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a full-blown stock-market meltdown.

Market optimism has waned as investors weighed mixed data, Fed guidance, and sector-specific risks after the S&P 500 hit eight record highs in September. Strong GDP and jobs data have tempered rate cut expectations, resulting in a slight market pullback, though 89% of traders still predict an October rate reduction. Beyond shifting rate cut expectations, seasonal weakness, upcoming earnings, an...

Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea , Sept.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond. The funding, distributed through the Gilead Foundation, will build on the company's ongoing work to cultivate a r...

Gilead Sciences is upgraded to 'Buy' as YEZTUGO's FDA approval strengthens its dominant HIV franchise and long-term outlook. GILD's valuation remains attractive, with a P/E of 14.74 and significant upside if revenue growth improves to low-to-mid single digits. While Cell Therapy and Liver Disease portfolios face headwinds, TRODELVY's expansion and LIVDELZI's launch offer meaningful optionality.